Efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia

Moo Yong Rhee, Cheol Ho Kim, Youngkeun Ahn, Joon Han Shin, Seung Hwan Han, Hyun Jae Kang, Soon Jun Hong, Hae Young Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Purpose: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and hyperlipidemia. Patients and Methods: Eligible patients, after more than 4 weeks of therapeutic lifestyle change, were randomly assigned to three groups: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV), 20 mg rosuvastatin (RSV), or 5 mg nebivolol (NEBI). Treatments lasted 8 weeks. Results: Efficacy was analyzed using data from 276 patients. Sitting systolic and diastolic blood pressures differed between the NEBI/RSV and RSV groups (LSmean difference = -5.89 and -5.99 mmHg; 95% confidence interval [CI] = -9.88 to -1.90 mmHg and -8.13 to -3.84 mmHg, respectively). Reductions in the two pressures did not differ between the NEB/ RSV and NEB groups. The percent reduction in low-density lipoprotein (LDL) cholesterol differed between the NEBI/RSV and NEBI groups (LSmean difference = -47.76%, 95% CI = -52.69 to -42.84%) but not between the NEBI/RSV and RSV groups. The blood pressure (BP) control rate was higher in the NEBI/RSV group than in the RVS group (51.09% vs 29.67%, p = 0.003). The LDL cholesterol goal achievement rate was higher in the NEBI/ RSV group than in the NEBI group (85.87% vs 11.83%, p < 0.001). The incidence of adverse drug reactions in the NEBI/RSV, RSV, and NEBI groups was 8.51%, 7.45%, and 8.60%, respectively (p = 0.950). Conclusion: Nebivolol plus rosuvastatin treatment is effective in reducing BP and LDL cholesterol levels and is safe in patients with hypertension and hypercholesterolemia without the loss of BP or the LDL cholesterol-lowering effect of each drug.

Original languageEnglish
Pages (from-to)5005-5017
Number of pages13
JournalDrug Design, Development and Therapy
Volume14
DOIs
Publication statusPublished - 2020

Bibliographical note

Funding Information:
C.H. Kim has received lecture honoraria from GlaxoSmithKline and Hanmi Pharmaceutical Co. Ltd and research grant from Merck Sharp & Dohme, LG Life Sciences Ltd., and Boryung Pharmaceutical Co. Ltd.

Funding Information:
M.Y . Rhee has received lecture honoraria from Pfizer Inc., LG Life Sciences Ltd., Boehringer Ingelheim Pharma GmbH & Co. KG., Hanmi Pharm. Co. Ltd., Y uhan Co. Ltd., and Boryung Pharmaceutical Co. Ltd.; consulting fees from Hanmi Pharm. Co. Ltd. and Shin Poong Pharma. Co. Ltd.; research grants from Boryung Pharmaceutical Co. Ltd. and Dong-A Pharmaceutical Co. Ltd.; and reports personals fees from Pfizer Inc. and

Funding Information:
Y . Ahn has received research grants from Medtronic Korea, Boston Scientific corporation, Abbott Corporation, and Qualitech Korea.

Funding Information:
The primary study was initiated and supported financially by Elyson Pharmaceutical Co., LTD. The company was involved in all stages of the study conduct and design. Elyson Pharmaceutical Co., LTD. also took responsibility for all costs associated with the development and publishing of the manuscript. This research was supported by the Ministry of Trade, Industry and Energy (Korea), the Korea Evaluation Institute of Industrial Technology (Korea) grant (No.10052298).

Funding Information:
The primary study was initiated and supported financially by Elyson Pharmaceutical Co., L TD. The company was involved in all stages of the study conduct and design. Elyson Pharmaceutical Co., L TD. also took responsibility for all costs associated with the development and publishing of the manuscript. This research was supported by the Ministry of T rade, Industry and Energy (Korea), the Korea Evaluation Institute of Industrial T echnology (Korea) grant (No.10052298).

Publisher Copyright:
© 2020 Rhee et al.

Keywords

  • Hypercholesterolemia
  • Hypertension
  • Nebivolol
  • Rosuvastatin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia'. Together they form a unique fingerprint.

Cite this